On Tuesday 31 October, the European Commission authorised the Nuvaxovid anti-Covid-19 vaccine for Omicron strain XBB.1.5, developed by Novavax.
This is an “important step in the fight against the disease. It is the first protein-based adapted vaccine authorised for this autumn and winter season”, the Commission noted.
In the third autumn after the discovery of Covid-19, European health authorities fear that a poor vaccine recall campaign could be the cause of a resurgence of the virus,...